ABSI · Absci Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ABSI. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ABSI · Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Live Quote
BUY (score +7) · 12-1 mom 81.1% · RSI 58.8 · above_both · -11.8% from high
Targets blend Wall Street consensus (10 analysts: low $4.10 / mean $9.61 / high $15.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
recent analyst:skip 17.1h ago < cooldown 168h, no material change
Anti-signals for low liquidity, dilution, and high cash burn (~$100M/yr on $125M cash) create unacceptable structural risk; combined with a binary H2 2026 catalyst priced into extreme IV and a >130% YTD run, there is no favorable entry or income structure that justifies the risk.
Absci is an AI-native clinical-stage biopharma whose lead program ABS-201 targets prolactin receptor (PRLR) for androgenetic alopecia and endometriosis. The June 5 8-K was routine (annual meeting), but the real near-term catalyst is Phase 1/2a HEADLINE trial interim proof-of-concept data expected H2 2026 — all four SAD cohorts have been dosed with favorable safety, MAD dosing initiated. Chief Innovation Officer Andreas Busch made a substantial open-market purchase of 100,000 shares at $2.29 in March 2026 (~$229K), and options flow is overwhelmingly bullish call-skew. However, the stock has already run ~134% YTD and sits near its 52-week high, trading above both MAs with no obvious entry point for a new long position without pulling back.
ABSI is a clinical-stage AI-native biopharmaceutical company whose shares have doubled year-to-date on the back of positive early Phase 1 data for lead asset ABS-201 (anti-PRLR antibody in androgenetic alopecia and endometriosis). The Q1 2026 earnings report (filed May 7) confirmed all four planned SAD cohorts dosed with favorable safety, MAD cohort initiated, and a new pipeline program (ABS-202) disclosed. Smart money shows one significant insider open-market purchase by Chief Innovation Officer Andreas Busch (100K shares at $2.29 in March 2026), plus director Menelas Pangalos buying on market. No CEO or CFO purchases are present; the CFO was net-selling for tax withholding during a vest. The stock is near its 52-week high ($5.90 vs. $6.235 high) with an RSI of 79 — deeply overbought short-term despite strong medium-term momentum and a bullish analyst consensus (7 analysts, median target ~$8). Valuation metrics are meaningless for a pre-revenue biotech; the narrative hinges entirely on Phase 1/2a ABS-201 proof-of-concept data expected in H2 2026. Options flow is heavily call-biased with a 0.19 put/call ratio and net $55K directional bias, but no whale blocks.